Unlocking Urologic Oncology Innovation QuickFire Challenge™
The American Urological Association, together with Johnson & Johnson, is thrilled to recognize Andromeda Surgical, Nanobots Therapeutics, and Tiller Therapeutics as the awardees of the Unlocking Urologic Oncology Innovation QuickFire Challenge.
Innovators from across the globe were invited to submit their transformative potential solutions to help improve the treatment and care of patients with bladder and prostate cancers.
These three awardees are being recognized for their potentially groundbreaking solutions aimed at reshaping the future of urologic cancer treatment:
Andromeda Surgical
Andromeda Surgical is building autonomous surgical robots for endourology with the potential to make surgical procedures safer, easier to learn, and more efficient.
Nanobots Therapeutics
Nanobots Therapeutics is developing a proprietary platform of enzyme-powered nanobots that aim to penetrate tissues with superior efficacy, with the potential to improve therapeutic drug distribution, penetration and accumulation in target tissues.
Tiller Therapeutics
Tiller Therapeutics is developing subcutaneously delivered targeted small molecule-drug conjugates with the aim to safely and effectively treat solid tumor oncology indications with high potency and low off-tumor toxicity.
The awardees will receive award funding from a total pool of up to $300,000 and mentorship from experts across Johnson & Johnson.*
*Subject to terms and conditions of applicable QuickFire Challenge and execution of an award agreement